Dirt Road Consultants Inc.
Your guide in the commercialization/ market access of cell & gene therapy (CGT) products
​
Which cell & gene therapies are we talking about here?
Dirt Road's consulting services are particularly valuable for CGT products with most of these characteristics:
One-time, potentially curative therapies
Therapies administered in a limited number of facilities
Treatment costs that are $400K - $3.5M
Market examples include:
Luxturna & Zolgensma (gene therapies) ​
Yescarta & Breyanzi (CAR-T cell therapies)
Why work with a CGT
commercialization/market access
consultant?
The road to reimbursement for most biologics is long and challenging, but by now, that road is asphalted and striped, with clear milestones and signage.
By contrast, the reimbursement road for cell & gene therapy (CGT) products is like a muddy, pothole-laden, primitive path for which no GPS guidance exists.
So where do you turn?
Start by considering Dirt Road Consultants as your seasoned guide for a successful CGT commercialization/market access journey.
Why choose
Dirt Road Consultants?
CGT manufacturers need guidance from consultants with real-world experience in CGT commercialization and market access. The list of real-world CGT consultants is very small right now, and even smaller if you want someone well-versed in almost all essential parts of a CGT go-to-market strategy.
Dirt Road can provide consulting that's customized for the challenges your unique product will face, including:
​
Developing & executing market access strategies and tactics that are specific to your CGT product
Working across a manufacturer's clinical, financial, and marketing teams to build a coherent approach to optimizing patient access to CGT products
Optimizing approaches for identifying & capturing patients for your CGT product
Creating valuable outcome/value-based rebate agreements
Vetting your hospital/specialty distributor partners
Identifying and addressing Insurer/Employer CGT benefit design changes that will impact a CGT's reimbursement/coverage
Discovering the hurdles and opportunities posed by CGT-focused cost containment vendors
Assessing your risks related to upcoming CGT-related actions by reinsurers
Who do I work with at Dirt Road?
As the CEO of Dirt Road Consultants, Eric Trepanier is guiding cell & gene therapy (CGT) manufacturers & their investors up the uniquely challenging road they face in commercializing their revolutionary products.
His deep knowledge of the CGT space and health insurance springs from his many years as a Senior Internal Consultant with Seattle-based Premera Blue Cross, where he led the development of Premera’s multi-pronged cost containment solutions for CGT, molecular diagnostics, and opioid treatments.
​
Eric holds a B.A. in Business Organization & Environment from the University of Washington, as well as an M.B.A. (finance concentration) from Seattle University.